The appeal panel of NICE, the health technology appraisal institute for England and Wales, has upheld an appeal by the charity Solving Kids’ Cancer against NICE’s decision not to recommend United Therapeutics Corp.'s Unituxin (dinutuximab) for use in a small number of children with high-risk neuroblastoma.
The panel agreed with the appellant that NICE had exceeded its powers and that its recommendation was unreasonable in the...







